N06AB03 fluoxetine
ATC group of level 5 – chemical substance · in plain English: antidepressants
This site has the patient leaflet or the SPC of 18 medicines in this group.
- 13 prescription only (POM)
- 2 no longer supplied or not available
Active substance: Fluoxetine – all medicines with this substance, also in combinations.
Place in the ATC classification
How to read ATC codes – what the levels mean and what a code does not tell you.
- N Nervous system drugs 4,502 medicines
- N06 Psychoanaleptics 771 medicines
- N06A Antidepressants 359 medicines
- N06AB Selective serotonin reuptake inhibitors 80 medicines
- N06AB03 fluoxetine 18 medicines
- N06AB Selective serotonin reuptake inhibitors 80 medicines
- N06A Antidepressants 359 medicines
- N06 Psychoanaleptics 771 medicines
Medicines
Other groups of the same level
- N06AB04 citalopram 9 medicines
- N06AB05 paroxetine 14 medicines
- N06AB06 sertraline 12 medicines
- N06AB08 fluvoxamine 6 medicines
- N06AB10 escitalopram 21 medicines
Other names of the ATC group
- Czech: N06AB03 Fluoxetin
- French: N06AB03 fluoxétine
- German: N06AB03 Fluoxetin
- Spanish: N06AB03 Fluoxetina
- German: N06AB03 Fluoxetin
- Italian: N06AB03 Fluoxetina
- Polish: N06AB03 Fluoksetyna
- Turkish: N06AB03 fluoksetin
- Portuguese (Brazil): N06AB03 Fluoxetina
- Slovak: N06AB03 Fluoxetín
- German (Switzerland): N06AB03 Fluoxetin
- French (Switzerland): N06AB03 Fluoxétine
- Italian (Switzerland): N06AB03 Fluoxetina
- Dutch: N06AB03 Fluoxetine
- English (Canada): N06AB03 Fluoxetine
- French (Canada): N06AB03 Fluoxétine
Sources
- Patient leaflets and SPCs: the MHRA product information (products.mhra.gov.uk) and the European Medicines Agency (EMA)
- Active substances, ATC codes and legal categories: the NHS Dictionary of Medicines and Devices (dm+d), NHS Business Services Authority
- World Health Organization (WHO): ATC/DDD classification, group N06AB03
Contains public sector information licensed under the Open Government Licence v3.0.
Ask your doctor or pharmacist which medicine is right for you.
